cepharanthine has been researched along with epirubicin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arai, Y; Kakehi, Y; Kanba, T; Shichiri, Y; Yoshida, O; Yoshida, S | 1 |
| Ding, X; Gao, N; Gong, QH; Jia, GF; Jiang, XX; Lei, L; Li, J; Li, ZQ; Shen, LW; Wang, M | 1 |
2 other study(ies) available for cepharanthine and epirubicin
| Article | Year |
|---|---|
Intra-arterial infusion chemotherapy in combination with a biscoclaurine alkaloid, Cepharanthin, to treat bone metastasis arising from renal cell carcinoma.
Topics: Alkaloids; Angiography; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzylisoquinolines; Biopsy; Bone Neoplasms; Carcinoma, Renal Cell; Epirubicin; Humans; Ilium; Injections, Intra-Arterial; Kidney Neoplasms; Male; Middle Aged; Recurrence; Tomography, X-Ray Computed; Vinblastine | 1994 |
Cepharanthine sensitizes human triple negative breast cancer cells to chemotherapeutic agent epirubicin via inducing cofilin oxidation-mediated mitochondrial fission and apoptosis.
Topics: Actin Depolymerizing Factors; Antineoplastic Agents; Apoptosis; Benzylisoquinolines; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Epirubicin; Humans; Mitochondrial Dynamics; Molecular Structure; Oxidation-Reduction; Structure-Activity Relationship; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2022 |